The risk of pulmonary adverse drug reactions of rebamipide and other drugs for acid-related diseases: An analysis of the national pharmacovigilance database in South Korea
- 주제(키워드) drug-related side effects and adverse reactions , interstitial lung diseases , KIDS KAERS database , pharmacovigilance , rebamipide
- 주제(기타) Gastroenterology & Hepatology
- 설명문(일반) [Yang, Bo Ram; Lee, Jae-Young] Chungnam Natl Univ, Coll Pharm, Daejeon, South Korea; [Kim, Myeong Gyu] Ewha Womans Univ, Coll Pharm, 52 Ewhayeodae Gil, Seoul 03760, South Korea; [Kim, Myeong Gyu] Ewha Womans Univ, Grad Sch Pharmaceut Sci, 52 Ewhayeodae Gil, Seoul 03760, South Korea
- 등재 SCIE, SCOPUS
- OA유형 Green Published
- 발행기관 WILEY
- 발행년도 2022
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000190448
- 본문언어 영어
- Published As https://doi.org/10.1111/1751-2980.13075
- PubMed https://pubmed.ncbi.nlm.nih.gov/34965009
초록/요약
Objective The objective of this case/non-case study was to detect rebamipide-related pulmonary adverse events (AE) compared with other drugs for acid-related disorders based on population-level data. Methods From 2009 to 2018, AE reports on drugs for acid-related disorders, which are anatomical therapeutic chemical code A02B drugs, in the Korea Adverse Events Reporting System (KAERS) database were examined. The reporting odds ratio (ROR) was calculated, and the odds of reporting pulmonary AE for rebamipide and all other A02B drugs were compared. Furthermore, a stratified analysis according to patients' age and sex was conducted. Results Altogether 13 (0.05%) and 157 (0.11%) cases of pulmonary AE were reported for rebamipide and all other A02B drugs, respectively. The risk of reporting pulmonary AE was significantly lower for rebamipide than for all other A02B drugs (ROR 0.49, 95% confidence interval [CI] 0.28-0.87). The number of reports of pulmonary AE for rebamipide was significantly higher among patients aged >= 65 years than those aged <65 years (ROR 19.36, 95% CI 2.50-149.97). Conclusions Rebamipide was less often reported for pulmonary AE. However, healthcare professionals need to be aware of the risk of pulmonary AE in elderly patients.
more